Pacgen Biopharmaceuticals Appoints Christina Yip as Chief Financial Officer

Vancouver, BC, Canada, April 20, 2006 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today that it has appointed Christina Yip as its Chief Financial Officer (“CFO”). Ms. Yip joins Pacgen from Cardiome Pharma Corp. (“Cardiome”), where she served as Vice President of Finance and Administration and Assistant Corporate Secretary to the Board. During her 8 year tenure at Cardiome, Ms. Yip progressed from Controller to Vice President of Finance and Administration and was integrally involved in various corporate finance activities including TSX listing, NASDAQ listing, acquisition of two US life sciences companies, and various public and private financings. She is filling the CFO role previously held by Mr. Fred Huang, MBA, who has been promoted to Senior Vice President and Chief Operating Officer of Pacgen. “We are extremely pleased to have Christina Yip joining us as our new CFO”, said David J. Cheng, Ph.D., President and CEO of Pacgen. He added, “we feel that we have significantly strengthened our management structure with the addition of Ms. Yip and the experience she brings with her from Cardiome.”

About Pacgen

About Pacgen Pacgen Biopharmaceuticals Corporation is an international biotechnology company specializing in the development of innovative peptide therapeutics for the prevention and treatment of infectious diseases and immune system regulations where current therapies are inadequate or ineffective. Pacgen’s current clinical programs include drug candidates for the treatment of oral candidiasis in HIV-infected patients (phase I/II), prevention and treatment of acute respiratory distress syndrome (preclinical), prevention of ventilator-associated pneumonia (preclinical), and treatment of chronic Hepatitis B & C infections (research & development).

Pacgen is headquartered in Vancouver, British Columbia, Canada. For additional information, please visit

James Beesley, B.Sc., D.C.
Director of Corporate Communication
Pacgen Biopharmaceuticals Corporation
Tel: (604) 436-4388 Ext. 107

PDF icon news_release20060420.pdf